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The 2008 National Research Council report ‘‘Phthalates and Cumulative Risk Assessment: Tasks Ahead,’’
rejected the underlying premises of TEQ-like approaches – e.g., chemicals are true congeners; are metab-
olized and detoxiﬁed similarly; produce the same biological effects by the same mode of action; exhibit
parallel dose response curves – instead asserting that cumulative risk assessment should apply dose addi-
tion (DA) to all chemicals that produce ‘‘common adverse outcomes’’ (CAOS). Published mixtures data
and a human health risk assessment for phthalates and anti-androgens were evaluated to determine
how ﬁrmly the DA–CAOS concept is supported and with what level of statistical certainty the results
may be extrapolated to lower doses in humans. Underlying assumptions of the DA–CAOS concept were
tested for accuracy and consistency against data for two human pharmaceuticals and its logical predic-
tions were compared to human clinical and epidemiological experience. Those analyses revealed that
DA–CAOS is scientiﬁcally untenable. Therefore, an alternative approach was developed – the Human-Rel-
evant Potency-Threshold (HRPT) – that appears to ﬁt the data better and avoids the contradictions inher-
ent in the DA–CAOS concept. The proposed approach recommends application of independent action for
phthalates and other chemicals with potential anti-androgenic properties at current human exposure
levels.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Background and introduction
The USEPA (EPA)1 has established the use of relative potency ap-
proaches, i.e., toxic equivalent (TEQ)-like approaches, for mixtures
risk assessment. TEQ-like approaches assume that if the following
four key pharmacological or toxicological premises are met, (1)
chemicals are true congeners, (2) are metabolized and detoxiﬁed
by the same biological processes, (3) produce the same spectrum
of biological effects by the same mode of action, and (4) exhibit par-
allel dose response curves for the biological effect being modeled
(Safe, 1990), then one may assume that in mixtures, those chemicalsY-NC-ND license. 
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ronmental Protection Agency;
sticular dysgenesis syndrome.will behave according to dose addition (DA) for speciﬁc toxic effects.
The DA assumption treats chemicals as if they all behave as dilutions
of a single prototype chemical scaled according to their potencies
relative to the prototype. Thus, risks of exposure to mixtures of such
chemicals are assumed to be equivalent to the risk of exposure to the
total equivalent dose of the prototype chemical. Risk assessment
practices at EPA and other agencies have traditionally assumed inde-
pendent action (IA) for mixtures of chemicals thought to exert ef-
fects by dissimilar modes of action (ATSDR, 2001a,2001b; USEPA,
1986, 1989, 1999, 2000).
The difference between DA and IA has important practical
implications for cumulative risk assessment that can be illustrated
by a simple example. Consider a mixture of three nephrotoxic
chemicals, each present at one-half its threshold concentration
for producing tubular acidosis: IA would predict a sub-threshold
effect for the mixture (i.e., 0 + 0 + 0 = 0) whereas DA would predict
measurable tubular acidosis (0.5 + 0.5 + 0.5 = 1.5) (Borgert et al.,
2005). Thus, IA would predict that doses of chemicals far below
the observable response range would not increase the effect of
other chemicals present at concentrations near or within the
Fig. 1. Extrapolating DA requires parallel dose–response curves. In panel a, dose
response curves for chemicals Y, W and T are parallel and there is a constant
proportionality between the curves, illustrated by the arrows, reﬂecting the fact
that the potency differences are constant at every response level. (Y–T; Y–W) thus
give relative potency factors Z1 and Z2 for those chemicals, which enable prediction
of the dose-additive response for untested dose combinations by transforming any
dose of T or W to its equivalent dose of Y. DA Response [Y,T,W] = Response [Y + (T-
Z1) + (W-Z2)]. These relationships hold for any number of chemicals with parallel
dose response curves. In panel b, dose response curves for chemicals Y and T are not
parallel, resulting in a different proportionality between the curves at every
response level (dashed lines), reﬂecting a different relative potency Y-T at every
response level. Thus, there is no uniform function that will accurately transform T
into an equivalent dose of Y, and so predicting DA Response [Y,T] becomes highly
uncertain for doses not tested empirically. Uncertainties expand with increasing
numbers of chemicals with non-parallel dose response character.
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response.
The main obstacle to applying DA broadly for diverse groups of
chemicals has been the required demonstration that the underly-
ing TEQ premises are met (Safe, 1998). The latter has prompted
argumentation that the TEQ concept is too restrictive for cumula-
tive risk assessment. Indeed, the deﬁnition of DA does not include
TEQ requirements, as DA is a purely quantitative model of com-
bined action that does not require speciﬁc chemical, toxicological
or pharmacological properties and requires only that the underly-
ing dose response relationship is quantiﬁed according to a com-
mon biological metric. However, TEQ premises (Table 1) have
been included explicitly to increase the reliability of extrapolating
the DAmodel to dose ranges, chemical ratios, and species that have
not been tested empirically (Safe, 1998). Hence, requiring similar-
ity of mode of action and biological effects serves to reduce the po-
tential for differences in the molecular, cellular and physiological
response characteristics of different mixtures components from
producing non-dose-additive combined action. Consequently,
inclusion criteria (Table 1) reduce the potential for pharmacoki-
netic differences to alter DA combined action expected at molecu-
lar, cellular and physiologic levels based on similar modes of action
and toxic effects, and increase conﬁdence in treating a mixture of
chemicals as if it were the total equivalent dose of the prototype
chemical alone. In contrast, chemicals with non-parallel dose re-
sponse curves have different relative potencies at different doses
and thus, cannot reliably be treated as simple dilutions of a proto-
type chemical across all doses and ratios (Fig. 1).
One prominent example of how rejecting TEQ premises may
lead to misinterpretation of data and over-interpretation of risk
is the report ‘‘Phthalates and Cumulative Risk Assessment: Tasks
Ahead’’ by the National Research Council (NRC, 2008). The report
asserts that based on the available data for phthalates and other
chemicals that result in androgen deﬁciency by different modes
of action (anti-androgens), cumulative risk assessment should be
conducted by applying DA to all chemicals that produce ‘‘common
adverse outcomes’’ (CAOS) rather than only to chemicals satisfying
TEQ criteria. Further, the report recommends DA to the exclusion
of other models of combined action, such as IA, irrespective of
whether chemicals exhibit parallel dose response curves for CAOS,
and places no other restrictions on the application of DA to CAOS
(DA–CAOS), including potency, exposure level, or mechanistic
assumptions regarding the anti-androgenic effects.
Some phthalates and other chemicals with potential anti-
androgenic properties have been found to produce malformations
of the developing male reproductive tract in rats, an observation to
which some researchers have attached the collective name
‘‘phthalate syndrome’’ (Foster, 2005). The mode of action for theseTable 1
Chemical similarity criteria for applying DA in cumulative (mixtures) risk assessments.
ATSDR mixture
risk assessmenta
ILSI cumula
risk criteria
Organ system (CAOS)
Target organ X X
Molecular target X X
Cellular target
Toxic intermediates X
Pharmacokinetics
Detoxiﬁcation pathways
Parallel dose–response curves
Chemical structure
a USDHHS (2001).
b Mileson et al. (1998) and USEPA (1999).
c USEPA (2000).
d Safe (1998).
e NRC (2008).effects is believed to involve an impairment of fetal Leydig and Ser-
toli cell function, leading to androgen deﬁciency in the developing
reproductive tract of male rats (David, 2006). Similar malforma-
tions have been reported in other species, however species differ-
ences in response to phthalates are apparent (Gaido et al., 2007;
Johnson et al., 2011; Lambrot et al., 2009; Hallmark et al., 2007).
Based on certain similarities between these malformations in ro-
dents and a so-called testicular dysgenesis syndrome (TDS) in hu-
mans (Skakkebaek et al., 2001), some have speculated that TDS
may be caused by exposure to anti-androgenic chemicals (Skakke-
baek et al., 2001; Foster, 2005).
Mixtures studies (Table 2) conducted by two research groups,
one based at universities in Europe (Christiansen et al., 2008,
2009; Hass et al., 2007; Metzdorff et al., 2007) and the other at
EPA (Hotchkiss et al., 2004; Howdeshell et al., 2007, 2008b; Rider
et al., 2008) have reported DA combined effects on the developing
male reproductive tract of rats for anti-androgens that differ in
molecular structure as well as in their mechanism of action and
pattern of anti-androgenic effects. Based on those ﬁndings, it has
been reasoned that limiting the application of DA only to chemicals
that ﬁt TEQ criteria may be insufﬁciently inclusive and thus,tive
b
EPA mixture
risk assessmentc
EPA TEQ
approachd
DA–CAOS
(NRC)e
X
X X
X X
X X
X
X
X
X X
X
Table 2
Mixture studies of anti-androgens in rats.
Study Chemicals Mixture design Model type consistent with mixture data
Hass et al. (2007)a Vinclozolin 1 ratio DA ﬁt most data; did not test IA
Flutamide 5 doses
Procymidone
Metzdorff et al. (2007)a Vinclozolin 1 ratio DA ﬁt the data; did not test IA
Flutamide 5 doses
Procymidone
Christiansen et al. (2008)a Vinclozolin 1 ratio Did not formally test a model; concluded that results exceed IA
Flutamide 2 doses
Procymidone
Christiansen et al. (2009)a Diethylhexyl phthalate 1 ratio DA and IA equally ﬁt most data; synergism observed for external
malformationsVinclozolin 3 doses
Prochloraz
Finasteride
Hotchkiss et al. (2004)b Benzylbutyl phthalate 1 ratio Did not formally test a model
Linuron 1 dose
Howdeshell et al. (2007)b Di(n)butyl phthalate 1 ratio DA and IA ﬁt some endpoints; DA ﬁt better than IA for most
endpointsDiethylhexyl phthalate 1 dose
Howdeshell et al. (2008b)b Butyl benzyl phthalate 1 ratio DA ﬁt; Did not test IA
Diethylhexyl phthalate 7 doses
Di(n)butyl phthalate
Diisobutyl phthalate
Dipentyl phthalate
Rider et al. (2008)b Vinclozolin 1 ratio DA-based models ﬁt data; IA did not ﬁt data
Procymidone 4 doses
Prochloraz
Linuron
Butyl benzyl phthalate
Diethylhexyl phthalate
Di(n)butyl phthalate
Benson (2009)b Butyl benzyl phthalate Risk Assumed Hazard Index Approach, consistent with DA
Diethylhexyl phthalate Assessment based on common
mode of action and adverse
outcome
Di(n)butyl phthalate Estimated mean, upper 95% CI and maximum human exposures
compared to RfDs 100-fold lower than observed mixture effects in
rats (1000-fold lower for diisononyl phthalate)
Diisobutyl phthalate
Diisononyl phthalate
Dipentyl phthalate Concluded that exposures are within acceptable risk levels
Kortenkamp and Faust
(2010)a
Butyl benzyl phthalate
Diethylhexyl phthalate
Di(n)butyl phthalate
Risk Assumed Hazard Index Approach, consistent with DA
Diisobutyl phthalate Assessment based on DA–CAOS
concept
Estimated mean and upper 95% CI of human exposures compared
to RfDs 200–500-fold lower than observed mixture effects in ratsDiisononyl phthalate
Vinclozolin
Prochloraz
Procymidone Linuron Concluded that 95% UCI exceeds acceptable risk levels
Fenitrothion
p,p0-DDE
Brominated diphenyl ether 99
Bisphenol A
Butyl paraben
Propyl paraben
a Studies conducted by the researchers at European universities.
b Studies conducted by the researchers at EPA.
C.J. Borgert et al. / Regulatory Toxicology and Pharmacology 62 (2012) 313–328 315produce insufﬁciently conservative human health risk assessments
that fail to protect from TDS (NRC, 2008). Subsequently, two hu-
man health risk assessments have been conducted using NRC’s
assumptions, both of which employed a hazard index calculation
to estimate risks (Table 2). One considered exposure to a mixture
of six phthalate esters (Benson, 2009), while the other utilized
the full DA–CAOS concept, considering exposure to a mixture of
15 potential anti-androgens spanning a range of chemical struc-
tures and modes of action including phthalate esters, pesticides,
and industrial chemicals (Kortenkamp and Faust, 2010).2. Analysis of mixtures studies, risk assessment of anti-
androgens, and predictions of DA–CAOS
The DA–CAOS concept obviously contravenes well-established
pharmacological principles for deﬁning relative potency of adverse
outcomes. In view of this, an in-depth analysis of the empirical and
theoretical foundations of the DA–CAOS concept and the respectivepractical consequences of its use was carried out. As well, potency
assumptions made in risk assessments based on the DA–CAOS con-
cept were evaluated. The following analyses were conducted:
(i) An evaluation of the extent to which the study designs
employed to test mixtures (Table 2) can support the extrap-
olation of DA versus IA to lower, untested doses and chemi-
cal ratios.
(ii) A statistical analysis of variability within the published data
for one endpoint evaluated in the mixtures studies as an
example to illustrate the uncertainty that might evolve from
extrapolation of the DA–CAOS assumption to lower,
untested doses and chemical ratios.
(iii) A consideration of whether the DA–CAOS concept can be
reconciled with the pharmacological basis underlying rela-
tive potency approaches.
(iv) an evaluation of the logical extensions of the DA–CAOS con-
cept and resulting risk assessment for consistency with
human clinical and epidemiological observations, and;
316 C.J. Borgert et al. / Regulatory Toxicology and Pharmacology 62 (2012) 313–328(v) A comparison of humans versus rat sensitivity to chemicals
with anti-androgenic properties to test the premise and key
default assumption of the risk assessment based on DA–
CAOS (Kortenkamp and Faust, 2010), that the developing
male reproductive tract of humans responds to chemicals
at doses two orders of magnitude lower than those required
to affect rats.
As shown below, these ﬁve analyses demonstrated that the DA–
CAOS concept and the risk assessments conducted per its premises
are scientiﬁcally untenable. Consequently, an alternative approach
– the Human-Relevant Potency-Threshold (HRPT) approach – was
developed to better ﬁt the data and to avoid the contradictions that
arise in using the DA–CAOS concept.2.1. Study designs
Five criteria for evaluating interaction studies used in risk
assessment have been deﬁned (Borgert et al., 2001) and were used
to assess the mixtures studies listed in Table 2. Criterion 1 ad-
dresses the fact that the better deﬁned the dose response parame-
ters for the individual chemicals, the more reliably distinctions can
be drawn between different combined effect models. Criterion 2
requires that non-interaction model(s) be explicitly deﬁned since
inferences of greater-than-additive (synergy) or less-than-additive
(antagonism) are typically made on the basis of statistically signif-
icant departures from a deﬁned non-interaction model.2 Usually,
DA and IA are the competing models of non-interaction tested. Cri-
terion 3 requires testing an adequate number of combinations across
a sufﬁcient dose range to meet the goals of the study. The latter is
important as combination effects can vary with the concentrations
and with the ratios of mixture constituents. Criterion 4 requires for-
mal statistical tests to distinguish the combined response from the
response predicted by the non-interaction model. Prerequisite for a
robust statistical analysis is to account for biological variation and
experimental error. Finally, Criterion 5 requires the evaluation of
interactions at a relevant level(s) of biological organization. Combi-
nation effects measured at molecular, cellular and higher-order
physiological endpoints may be necessary to gain an unambiguous
understanding of the biological response to a mixture.2.1.1. Study designs: Dose ranges and ratios
Conducting experiments in whole animals or human subjects
often prevents satisfying all ﬁve criteria (Price et al., 2002; Borgert
et al., 2001) due to the difﬁculty of obtaining sufﬁcient dose–re-
sponse information. Those limitations affect the studies under con-
sideration here (Table 2), as acknowledged by some of the authors
(e.g., Hass et al., 2007). Nonetheless, greater conformity with the
ﬁve criteria provides for more unequivocal data interpretation
across the concentration ranges tested. In contrast, studies fulﬁll-
ing fewer criteria or with less stringency must be interpreted with
more caution, i.e., limiting the interpretation to the speciﬁc doses
and ratios tested. Uncertainties are compounded when combina-
tion effects are extrapolated to doses and ratios not tested
empirically.
The interpretations supportable from a mixture study are inher-
ently dependent on the quality of dose–response data available for
the individual mixture components, which should be tested across
a concentration range and with a sufﬁcient number and spacing of
doses to reveal maxima, minima, points of inﬂection, and regions
of linearity (Borgert et al., 2001). The mixtures studies (Table 2)
used for the risk assessment of anti-androgens (Kortenkamp and2 Models that test directly for synergism have been devised (e.g., Barton et al.,
1993; Laska et al., 1994) but have not gained wide acceptance.Faust, 2010) varied widely in their characterization of dose re-
sponse data for the individual chemicals. In some studies, as many
as seven doses were tested while in other studies, dose response
data from prior experiments and different rat strains were used
as surrogates. In most instances, dose response models were used
to curve-ﬁt the data, and model parameters obtained from single
chemical experiments were used to predict mixture effects.
All of the studies employed single ratios of chemicals to simu-
late mixture effects (Table 2). This design is often referred to as a
ﬁxed ray design (Cassee et al., 1998) and has advantages over
experimental designs employing only a single concentration of
the mixture components because it allows local interpretations be-
yond one data point. A ﬁxed ray design may be the broadest study
design achievable in live animals due to limitations on the man-
ageable size and number of dose groups (Cassee et al., 1998; Price
et al., 2002), but this feature should constrain the interpretations to
the ratios tested and preclude extrapolation to untested ratios.
Several of the studies chose individual constituent ratios predicted
to yield an equal contribution from each component across the en-
tire range tested, however, conﬁdence in that prediction is unjusti-
ﬁed unless all components have parallel dose response
characteristics. It is highly questionable whether the slopes of
the dose response data for male reproductive tract effects of the
individual chemicals are sufﬁciently similar to support this
assumption. Although DA assumptions and calculations can be
made for chemicals with non-parallel dose response curves, the
reliability of those calculations diminishes rapidly as they are
extrapolated beyond the ratios and concentrations tested empiri-
cally (Fig. 1) (Cassee et al., 1998; Borgert et al., 2001; Price et al.,
2002).
Although the mixtures studies (Table 2) all reported testing
‘‘low doses’’ of the mixture components administered to dams, this
term must be understood in the context of the physiological sys-
tem. The doses tested appear to be within an order of magnitude
of the observable response range for physiologically relevant
anti-androgenic effects. For example, Rider et al. (2008) reported
that the mixture doses used in their study were below the observa-
ble response range for malformations of the developing male
reproductive tract in rats, i.e., procymidone at a maternal dose of
7.5 mg/kg/day. Contrary to the latter no observable effect assump-
tion, Metzdorff et al. (2007) reported that 5 mg/kg/day procymi-
done produced statistically signiﬁcant changes in seminal vesicle
weight, and 10 mg/kg/day produced changes in testis, ventral pros-
tate, levator ani/bulbocavernosus muscle, and bulbourethral gland
weights, thus suggesting that Rider et al. (2009) were testing mix-
tures containing doses of procymidone well within the observable
effect range for anti-androgenic action. Further, although Rider
et al. (2008) reported that vinclozolin was without statistically sig-
niﬁcant effects at 3.75 mg/kg/day, Metzdorff et al. (2007) reported
that a slightly higher dose of 10 mg/kg/day vinclozolin produced
statistically signiﬁcant changes in epididymal, ventral prostate,
and seminal vesicle weights. These examples demonstrate the sub-
stantial variability that exists in deﬁning the observable response
range, especially for endocrine-sensitive endpoints (Ashby, 2003).
Because the comparison of no-interaction dose–response models
for mixtures, i.e., DA versus IA, entirely depends on the precision
of the no observable effect estimate, this latter precision must
inﬂuence the conﬁdence placed on the interpretations drawn from
such data, as exempliﬁed below.
Rider et al. (2008) also showed that individual phthalates (dibu-
tyl phthalate and diethylhexyl phthalate) failed to increase the
incidence of male reproductive tract malformations at maternal
doses below 500 mg/kg/day,3 but that in a mixture with the anti-3 Ranges inferred from Fig. 1 of the cited paper.
ab
Fig. 2. Conceptual Model for DA–CAOS. Different line patterns a, b, and c represents
chemicals with anti-androgenic potential that produce CAOS via different modes of
action. (S) indicates the dose range where mixture experiments (Table 2) have been
performed relative to the dose–response curves for observable effects (Q). Panel a:
Generation of dose addition data. Available data suggest that sub-effective doses of
a few such chemicals may produce a DA response when the dose of each is within S,
i.e., near the observable response region Q. Panel b. Extrapolation of mixture data to
DA–CAOS model. The DA–CAOS concept assumes that doses of such chemicals far
below the observable response region (S) also operate by DA and may produce an
observable response if sufﬁcient numbers of chemicals are present. However, no
data support this extrapolation (P).
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linuron, doses of 75 mg/kg/day of butyl benzyl phthalate, dibutyl
phthalate and diethylhexyl phthalate contributed to an increased
incidence of observable malformations.4 This suggests that the com-
bination of the three phthalates (75 mg/kg/day each, thus a total of
220 mg/kg/day) would provide for an effect greater than the no ob-
servable effect estimate demonstrated for 500 mg/kg/day of dibutyl
phthalate or diethylhexyl phthalate. In a previous study by the same
group, these three phthalates reduced fetal testosterone production
at doses of 300 mg/kg/day individually and at doses of 60 mg/kg/day
in combination with two other phthalates (Howdeshell et al.,
2008b), suggesting that the three phthalates alone (butyl benzyl
phthalate, dibutyl phthalate and diethylhexyl phthalate) would re-
duce fetal testosterone production when combined in a mixture at
approximately 100 mg/kg/day each. Thus, although the doses of
phthalates and other chemicals used in these mixtures were statisti-
cally below their individual no effect levels on male reproductive
tract malformations in particular studies, they are nonetheless close
to the dose range that produces a clear reduction in fetal testoster-
one individually and in mixtures. Slight differences in the experi-
mental protocols, time of dosing, or rat strain could explain these
differential responses. Regardless of the underlying reason, this com-
parison underscores how imprecise the distinctions might be regard-
ing the no observable effect level for androgen sensitive tissues, and
illustrates that the label ‘‘low dose’’ cannot be taken to mean a dose
that is without a physiologically relevant anti-androgenic effect. To
put the doses used in these rat studies into perspective with hu-
man-relevant exposures, the ‘‘high intake’’ level of vinclozolin and
procymidone (9 lg/kg/day) and butyl benzyl phthalate (4 lg/kg/
day), dibutyl phthalate (6 lg/kg/day), and diethylehexyl phthalate
(3.6 lg/kg/day) estimated for the US population are roughly 3–4 or-
ders of magnitude lower (Kortenkamp and Faust, 2010).
Despite limitations just described, the DA–CAOS concept was
extended well below the dose range where DA was demonstrated
(Kortenkamp and Faust, 2010; NRC, 2008). Fig. 2a illustrates the
general study designs that have produced DA mixture effects from
‘‘no-effect’’ combinations of anti-androgenic chemicals with differ-
ent modes of action. Fig. 2b illustrates how the DA–CAOS approach
extrapolates the same studies depicted in Fig. 2a to far lower doses
of the mixture components, which were not tested empirically. The
conservatism introduced here goes well beyond extrapolating ob-
served toxicity from high to low doses; that conservatism is com-
pounded by the choice of DA over IA based on very limited study
designs.2.1.2. Study design: Endpoints and dose response metrics
Mixtures studies on potential anti-androgenic chemicals consis-
tently report conformity with the DA model of combined action,
however, those studies report inconsistent results as to whether
the data also conform to IA (Table 2). For example, one study re-
ported that IA under-predicted combination effects and only DA–
models adequately ﬁt the data for all malformations combined (Ri-
der et al., 2008), whereas another study (Christiansen et al., 2009)
found that the data for most endpoints could be ﬁt adequately by
either model, with some greater-than-additive exceptions. The
inconsistency of results obtained from the different approaches
used by these two research groups could be due to any number
of factors, including the animals used, the exact doses tested, the
way endpoints were measured, or slight differences in the mathe-
matical algorithms used for DA and IA.
Although the application of DA is not constrained to any partic-
ular type of effect, the use of scored endpoints, which are inher-
ently subjective (Haschek et al., 2010), presents challenges for4 Inference from Fig. 3 of the cited paper.analyzing experimental variance not typically encountered when
continuous variables are measured according to objective scales.
Several of the mixtures studies listed in Table 2 assessed scored
endpoints, but it is unclear how variance was assessed statistically
for these endpoints, if it was addressed at all. Except for gubernac-
ular underdevelopment (not categorized as a malformation above
a certain length), all other male reproductive tract malformations
were combined into a single group, further complicating the
assessment of experimental variance; it is unclear if or how this
was addressed in the statistical analysis (Howdeshell et al., 2007;
Rider et al., 2008). Other studies categorized fetal malformations
according to a four-point scale that included none observable,
mild, moderate, or severe (Christiansen et al., 2008, 2009). To re-
duce those scores to a dichotomous variable suitable for statistical
analysis used to test DA versus IA combined effect models, moder-
ate and severe malformations were grouped together in the ‘‘mal-
formations’’ category, while mild malformations were grouped
together with no observable malformations in the ‘‘no-effect’ cate-
gory. Although this practice allows some statistical analysis of re-
sults, it introduces additional potential errors of interpretation.
IA predicts that no-effect doses of individual chemicals will also
produce no effect when combined. Therefore, including mild mal-
formations or gubernacular underdevelopment in the no-effect
category for single chemical responses, as was done in some anal-
yses (Christiansen et al., 2008, 2009) increases the chance that
malformations will be observed when so-called ‘‘no-effect’’ doses
of several chemicals are combined in the mixtures study. Because
malformation severity also increases with dose, these methods of
318 C.J. Borgert et al. / Regulatory Toxicology and Pharmacology 62 (2012) 313–328scoring and grouping malformations may have ensured rejection of
the IA model or biased the analysis toward synergism because a
slight increase in ‘‘dose’’ from the combination of agents would
raise certain mild malformations to the moderate/severe category.
The uncertainty introduced by this procedure was not addressed,
and methods for assessing its impact are lacking. The fact that
small differences in experimental protocol or analysis alter the re-
sults of the mixture experiment raises concerns as to the degree of
uncertainty inherent in interpreting the results for risk assessment.
The risk assessment of anti-androgens chose DA over IA based on a
stated preference for the more conservative model (Kortenkamp
and Faust, 2010), however, the implications of inconsistent results
for extrapolating to untested doses and mixture ratios appear to
have been overlooked.
2.2. Statistical analysis of variability
In order to provide an objective estimate of the potential uncer-
tainty contributed by the dose response information discussed
above, data presented in one of the published mixture studies
(Rider et al., 2008) was evaluated. Because the original raw data
were unavailable, data points were inferred from published ﬁgures
(Rider et al., 2008, Fig. 1). In order to be as consistent as possible
with the published study, the dose response model used to ﬁtFig. 3. Statistical analysis of uncertainty; isoboles created from Bootstrap procedure. 3–1
Dose addition (DA) deﬁnes a line connecting equally effective doses of Dose 1 and Dos
additive (antagonistic) dose combinations, below the line, greater-than-additive (synerg
would represent a doubling of the dose. The center panel shows a collection of isoboles a
mixture of doses. The right panel shows the output from one analysis, and depicts all of th
isobolograms will vary from sample to sample. 3–2: This variation is illustrated for the da
doses, and thus, the extent of uncertainty surrounding the DA prediction, is illustrated b
experiments as plotted on the abscissa. The lowest log (base-2) dose estimated to produc
to produce the same level of response is approximately log dose 3.2 (panel c), indicating t
within the observed data. The parallel lines correspond to isoboles for equi-effective do
levels is proportional to the variance at higher doses and response levels, i.e., nearly twthe published data (Rider et al., 2008) was also used in the analysis
presented here. Speciﬁcally, based on the data points inferred from
the graphs published by Rider et al. (2008) and the dose response
model they ﬁt to their data, a dose–response curve was developed
and then data points were generated from the theoretical curve. A
number of different samples were obtained in this way. Such iter-
ations of the dose–response experiment comprise a statistical
bootstrap procedure (Efron and Tibshirani, 1993), and the results
are presented in a series of isobolograms (Fig. 3). The variability
in the bootstrap samples is representative of that in the original
data, providing a clear picture of the range of doses consistent with
any particular level of response.
Isobolograms are a simple means of graphically evaluating data
on binary mixtures for conformity to DA. Doses of one of the mix-
ture components are plotted along the abscissa and the other along
the ordinate. The equation for DA describes a line connecting
equally effective doses of these two chemicals on the ordinate
and abscissa. All other equally effective doses, representing deﬁned
mixtures of both components, are DA if they fall on the line, less
than DA if they fall above the line, and greater than DA if below
the line. Since some degree of variability and experimental error
are inherent to the measurement of any observation or biological
endpoint, the lines of additivity representing DA combination
doses in an isobologram must be enveloped by statistical: The left panel is an isobologram for two agents, Dose 1 and Dose 2, at 50% response.
e 2 administered individually. Points above the line would demonstrate less-than-
istic). The dose is plotted on a log 2 scale, so a change from 2 to 4 on the log 2 scale
t different response levels. Again, each line represents a constant response over the
e isobolograms, from 5% to 95% response. As this is the output from one sample, the
ta inferred from Fig. 1 of Rider et al. (2008). The estimated variance in equi-effective
y comparing how the 95% effective dose for one mixture component changes across
e a 95% response is approximately 1.7 (panel e) whereas the highest dose estimated
hat the iso-effective dose of just one mixture component can vary nearly 2-fold even
ses at lower response levels indicate that the variance at lower doses and response
ofold.
Fig. 3 (continued)
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variance and/or experimental error will produce larger conﬁdence
intervals than assays with lower variance and/or experimental er-
ror (Borgert et al., 2005).
The variability attending any DA prediction can be estimated by
observing how the equi-effective dose of each mixture component
varies from experiment to experiment. The isobolograms shown in
Fig. 3(2), a–f indicate considerable variance within the published
data, despite the fact that the bootstrap procedure used to generate
the new ‘‘data’’ on which the isoboles in Fig. 3(2) were constructed
employed the underlying dose–response model that Rider et al.
(2008) concluded best ﬁt their data. Even within these contrived,
best-case experiments, nearly 2-fold variance is observed, indicat-
ing that this variability surrounds any DA conclusion, even within
the range of doses tested empirically. It is thus surprising that Ri-
der et al. (2008) unequivocally excluded IA for nearly all of the re-
ported combination effects, since this requires an absence of
overlap between IA and DA predictions after accounting for the
experimental variance. It is unclear how this variance was handled
in the analysis of combination effects (Rider et al., 2008). Similar to
the analysis presented here, other studies employed a bootstrap
procedure to assess variance, and on that basis, concluded that
both IA and DA predictedmost of the mixture responses (Metzdorff
et al., 2007).
It is critical to appreciate that for assessing risk, the DA–CAOS
theory extrapolates the DA model beyond the doses and ratios
tested in mixtures studies (Kortenkamp and Faust, 2010). Since
the apparent variance of the data within the range of doses tested
in those studies (Table 2) raises questions as to whether a single
model of combined action can be unequivocally declared the most
accurate, even for all mixture ratios within that dose range,extrapolation to much lower doses and different mixture ratios
would be quite tenuous. Little attention was given to the fact that
the uncertainty of the predictions will expand in accordance with
the variance in the data, other than to justify the choice of the
model on a preference for conservatism.
The statistical analysis presented here has implications for the
feasibility of selecting a ‘best’ model of combined action as well
as for future mixtures studies aimed at supporting such a determi-
nation. Unless the observed variance were so small that no signif-
icant overlap of DA and IA model predictions could occur as the
model is extrapolated across untested dose ranges, it would be fu-
tile to attempt to select a model of combined action based on a sta-
tistical analysis of mixtures data within the observed response
region. Indeed, the research group from Europe found that DA
and IA overlapped even within the dose regions tested (Table 2),
substantiating this point.
2.3. Relative potency and pharmacokinetics: Pharmacological
principles
In addition to the problems discussed above, the DA–CAOS the-
ory contravenes fundamental pharmacological principles of recep-
tor/enzyme afﬁnity, intrinsic activity, and potency. Afﬁnity is a
term referring to the strength of attachment between two mole-
cules and is applicable to interactions of a small ligand with a lar-
ger macromolecule such as an intracellular or membrane-bound
receptor, an ion channel, an enzyme, or speciﬁc binding protein.
For simplicity, all of these are referred to as ‘receptors‘ with the
understanding that the general principles apply to all such interac-
tions with macromolecules. The afﬁnity of a ligand for a speciﬁc
receptor determines its residence time of association, a parameter
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afﬁnity ligands have longer residence times. Intrinsic activity is
the relative ability of a drug-receptor complex to produce a maxi-
mum functional response and is sometimes used interchangeably
with efﬁcacy. However, ‘intrinsic activity’ refers to a cellular re-
sponse whereas ‘efﬁcacy’ is more often used in the context of a
clinical response. Assuming equivalent pharmacokinetic parame-
ters and afﬁnity, a drug with greater intrinsic activity would have
greater efﬁcacy. Potency is the intensity of effect produced per unit
of drug, and is a function of intrinsic activity and afﬁnity.
Because most receptor-based physiological responses can be
triggered when only a small fraction of available receptors are acti-
vated by a strong agonist (a ligand with high afﬁnity and intrinsic
activity), receptor ligands with very low afﬁnity and no intrinsic
activity (weak antagonists) will fail to interfere with endogenous
agonists unless their concentrations reach levels that obstruct
access to the receptor by shear mass action. The same principle ap-
plies to competitive inhibitors of enzymes involved in steroido-
genic pathways or to activators or blockers of ion channels in
cellular membranes. Thus, because of vastly different residence
times, ligands with very low afﬁnity spend such little time in con-
tact with a receptor that they produce no discernible interference
with high-afﬁnity ligands unless their concentrations reach a sufﬁ-
cient level that interference by mass action occurs. In other words,
low afﬁnity ligands cannot compete with high afﬁnity ligands by
their strength of attachment, but rather, only by shear numbers
of molecules that impede access to the receptor. This is why low
afﬁnity ligands have no discernible effects at low concentrations.
Even agonists with relatively similar afﬁnity but different intrinsic
activity are incapable of producing linear isoboles, commonly used
to detect DA (see Section 2.2 above), because the physiological re-
sponse reﬂects both afﬁnity and intrinsic activity. Drugs or chem-
icals that differ in intrinsic activity will necessarily compete at a
molecular site of action and will not produce a linear DA combined
response, as demonstrated mathematically and empirically by Tal-
larida (2006, 2007).
In contradiction of these principles, DA–CAOS posits, for exam-
ple, that any dose of a weak androgen receptor antagonist will
diminish the physiological activity of dihydrotestosterone by some
ﬁnite degree, irrespective of whether its afﬁnity approaches that of
a natural ligand. This demonstrably faulty premise provides the
underlying basis for the DA–CAOS supposition that chemicals
capable of reducing androgen levels at high doses will add to the
effect of weak receptor antagonists even at very low doses. In fact,
however, multiple chemicals given at doses incapable of affecting
physiological processes individually, by separate mechanisms,
would not be expected to produce a physiological effect in combi-
nation. A combined physiological effect would not be expected un-
less doses of those chemicals were on the cusp of producing overt
effects individually. In other words, fundamental pharmacological
principles dictate that a weak androgen receptor antagonist would
not produce a combination effect with an androgen synthesis
inhibitor or Leydig cell toxicant unless the doses were sufﬁcient
to reduce both the concentration of endogenous androgen and
the numbers of available receptors to levels near the critical min-
ima necessary for supporting normal physiology. The DA–CAOS
theory fails to recognize that the presence of myriad weak hor-
mone receptor agonists and antagonists in the environment would
fail to be DA in combination or to achieve physiological signiﬁ-
cance, in part because their weak properties cancel one another
and in part because their low afﬁnities and intrinsic activities pre-
clude it (Safe, 1998; Tallarida, 2006).
Furthermore, the role of pharmacokinetics and how these phe-
nomena may change with dose and ratio of mixture constituents is
often under-appreciated in discussions of the joint toxicity of
chemicals. This is important because pharmacokinetic alterationsunderlie the majority of documented interactions between chemi-
cals (Krishnan and Brodeur, 1994) and the dose-dependence of
many toxicity mechanisms, even for single chemicals (Slikker
et al., 2004). Obviously, the potential for concomitant administra-
tion to affect the absorption, distribution, metabolism and excre-
tion of chemicals in mixtures increases with dose and the
number of chemical constituents as the underlying processes that
control each reach the limits of their capacity. Such inﬂuences
would be of greatest consequence for highly potent compounds.
Without understanding how pharmacokinetic processes change
with dose and ratio of constituents, it is impossible to reliably
extrapolate combination models across different dose ranges and
chemical ratios. Neither the mixture studies of potential anti-
androgens (Table 2) nor the NRC report (NRC, 2008) considered
these issues.
2.4. Testing predictions of the DA–CAOS concept
Despite the uncertainties inherent in the published mixtures
studies and the unnecessary conservatism introduced into the risk
assessment by assuming DA at all chemical concentrations, it is
important to consider whether the logical extensions of the DA–
CAOS theory are nonetheless concordant with human clinical and
epidemiological experience. To test this concordance, an attempt
was made to reconcile the incidence of TDS in humans with appli-
cation of the DA–CAOS concept to the full suite of chemicals al-
leged to have anti-androgenic potential. As well, the DES dose–
response for male reproductive tract malformations was consid-
ered according to the DA–CAOS concept in light of extant informa-
tion regarding other environmental exposures during the period
when DES was administered to pregnant women.
2.4.1. Incidence of TDS and cumulative exposure to anti-androgens
The published risk assessment based on the DA–CAOS concept
(Kortenkamp and Faust, 2010) concludes that ‘‘...the cumulative
risks from anti-androgen exposures exceed acceptable levels for people
on the upper end of exposure levels,’’ i.e., the upper 95% conﬁdence
interval of human exposures to only 15 anti-androgenic chemicals.
This conclusion implies that pregnant women and their fetuses are
at an unacceptably high risk for anti-androgenic effects, and specif-
ically, that approximately 5% of male fetuses are at risk for devel-
opment of TDS. The authors also claim that 8% of all known
chemicals are likely to possess anti-androgenic potential, including
thousands of chemicals on the market in the European Union (Kor-
tenkamp and Faust, 2010). Presumably, similar exposures occur in
other industrialized nations. Logically extending the DA–CAOS the-
ory would thus project that the percentage of human fetuses at risk
for the development of TDS is actually much higher than 5% if
exposure to all chemicals with anti-androgenic potential were in-
cluded. Given the author’s contention that thousands of chemicals
marketed in Europe may have anti-androgenic potential, their pub-
lished risk assessment on 15 anti-androgens considered only 1% or
fewer of the relevant chemicals. If one further considers that in
utero exposures to over-the-counter analgesics have also been
linked to similar male reproductive tract disorders in rats and hu-
mans (Kristensen et al., 2011), the projected percentage of affected
fetuses should approach 100%, depending on exposure levels for
the various putative anti-androgens.
However, the actual incidence of TDS could not be nearly so
high, as the incidence of hypospadias and cryptorchidism have
been estimated at between 0.2–1% and 2–9% respectively (Toppari
et al., 2010). Even without considering the DA–CAOS theory, some
clinicians have questioned the etiologic role of industrial chemicals
in TDS (Thorup et al., 2010), asserting that the epidemiological data
do not support such a relationship. Their in-depth analysis of
the incidence and biology of these male reproductive tract
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effects caused by a common etiologic agent(s), instead pointing
to a complex array of clinical diagnostic, genetic, and other factors
that may be individually involved in the apparent increased inci-
dence of hypospadias, cryptorchidism, testicular cancer and other
malformations (Thorup et al., 2010). For example, an analysis by
Fisch et al. (2001) revealed that hypospadias was signiﬁcantly
associated with increasing maternal age as a consequence of more
women who delay childbearing until their mid-30s. It is also worth
noting that Sharpe (2003), who was initially one of the principle
proponents of the TDS hypothesis as a consequence of in utero/
neonatal exposure to a variety of weakly estrogenic compounds
from the environment, offered the following reassessment: ‘‘What
is reasonably clear is that all of the identiﬁed ‘‘environmental
estrogens’’ possess weak or very weak intrinsic estrogenic activity
whenmeasured by conventional in vitro and in vivo assays for estr-
ogenicity. . . By comparisonwith the potency of DES, for which there
[are] bothhumanand rodent data on incidence ofmale reproductive
developmental disorders following in utero exposure (or neonatal
exposure in rodents), it seems unlikely that any of the identiﬁed
environmental compounds could induce either cryptorchidism,
hypospadias or testis germcell cancer andonly a tinypossibility that
such compounds could affect sperm counts/sperm production.
. . .Based on estrogenic potency, human exposure to the most
potent environmental estrogenswould need to be at least 1000-fold
higher than this level for adverse effects relevant to the humanmale
to be induced, and such levels of exposure are remote.’’
2.4.2. Cumulative exposure to anti-androgens and clinical threshold
for DES
Because normal development of the male reproductive tract is
dependent on the androgen/estrogen ratio, the DA–CAOS theory
predicts that cumulative exposure to environmental estrogens,
anti-androgens, and other chemicals that can produce TDS-like
abnormalities will increase its incidence in a DA manner. Although
great concern has been generated over current cumulative expo-
sures to anti-androgenic chemicals, it is generally acknowledged
that human exposures to a wide array of chemicals capable of
affecting the developing male reproductive tract – both anti-
androgenic and estrogenic – have decreased since the period dur-
ing which diethylstilbestrol (DES) was administered to pregnant
women and its eventual removal from the market, in part for its
TDS-like effects induced in utero [see Section 2.5.1 for a detailed
discussion]. Polychlorinated biphenyls (PCBs) (Andric et al.,
2000a,b; Gray et al., 1999) chlorinated pesticides (Fernandez
et al., 2007; Kelce et al., 1995), and 2,3,7,8-tetrachloro-p-dioxin
(TCDD) (Gray et al., 1995, 1997) are but a few prominent examples
of chemicals with anti-androgenic potential to which human expo-
sures have been declining since the DES episode (Adeshina and
Todd, 1991; Axmon et al., 2008; Hays and Aylward, 2001; Hovinga
et al., 1992; Petreas et al., 2001; CDC, 2005; USEPA, 2006). Given
that use of high-dose over-the-counter analgesics, which have also
been associated with male reproductive tract malformations
(Kristensen et al., 2011), was also common during the era when
DES was given, it seems highly probable that exposures to chemi-
cals capable of producing TDS-like effects were substantial during
the DES episode, and most certainly higher than today.
If, as the DA–CAOS risk assessment predicts, a signiﬁcant pro-
portion of male fetuses experience anti-androgenic effects today,
at least as high a proportion would likely have experienced such
effects during the era of DES use in pregnancy. Assuming the
DA–CAOS theory, it would follow that any dose of DES should have
produced an observable increase in the incidence of TDS-like
effects above the predicted observable background of chemical-
induced male reproductive tract malformations. In contrast, no
clear increase was observed in the incidence of TDS-like effectswith the lower-dose regimens of DES (Dietrich, 2010; Golden
et al., 1998).
2.5. Human versus rat sensitivity
One reason the hazard index-based DA–CAOS risk assessment
(Kortenkamp and Faust, 2010) is irreconcilable with human clinical
and epidemiological evidence is it employed reference doses (RfDs)
that were developed without considering relevant data and physi-
ological knowledge concerning species-speciﬁc sensitivity for
chemical effects on the male reproductive tract (Cook et al.,
1999; Hallmark et al., 2007; Scott et al., 2009). The derived RfDs
incorporate uncertainty factors of 200–500 (Kortenkamp and
Faust, 2010), consistent with an assumption that adverse effects
on the developing male reproductive tract may be observed in hu-
mans at doses 200–500-fold lower than doses required to elicit
such effects in rats. In the absence of relevant human data, such
procedures are considered appropriate for extrapolating rodent
toxicity data to humans. However, direct human data are available
for many human pharmaceuticals, including drugs with anti-
androgenic and/or TDS-like effects. The assumptions made in the
risk assessment were thus tested against such human data. Data
were evaluated by comparing human versus rat data from (a) in
utero exposures to DES, a chemical that produces TDS-like malfor-
mations of rodent and human reproductive tracts by inducing
androgen deﬁciency secondary to functional disruption of Leydig
and Sertoli cells, and (b) human versus rat administration of
ﬁnasteride, an anti-androgen that produces androgen deﬁciency
by inhibiting conversion of testosterone to its active form,
dihydrotestosterone.
2.5.1. Human versus rat – DES
To test the premise that chemicals affect the developing male
reproductive tract of humans at doses 200–500 lower than in
rats, human clinical data on gestational exposure to DES were
compared with data from concordant exposures in the rat.
Although DES is a potent estrogen agonist that interferes with
Sertoli and Leydig cell function in rodents, some of its adverse ef-
fects on the male reproductive tract are complex, e.g., may in-
volve both estrogen (Couse and Korach, 2004) and androgen
pathways (Goyal et al., 2009; Rivas et al., 2003), and exhibit both
similarities and differences compared to pure estrogens such as
estradiol 17b (Adachi et al., 2004; Khan et al., 1998; Lassurguere
et al., 2003; Warita et al., 2010). In addition to reducing activity
of the steroidogenic acute regulatory protein (StAR) and other ef-
fects similar to those produced by some phthalates in rats (Guyot
et al., 2004; Howdeshell et al., 2008a; Ikeda et al., 2008), treat-
ment of neonatal rats with testosterone or dihydrotestosterone
prevents most effects of DES on the developing male reproductive
tract (Rivas et al., 2003; Goyal et al., 2009), providing evidence
that androgen deﬁciency or alteration of the androgen-estrogen
balance is involved in DES action. Loss of Leydig cell function, also
proposed for phthalate esters (David, 2006; Howdeshell et al.,
2007), is one of many anti-androgenic modes of action that can
result in androgen deﬁciency and is encompassed by the DA–
CAOS concept. Thus, the action of phthalate esters on fetal Leydig
and Sertoli cells appears to be more similar to DES than to the
other anti-androgens assessed in the mixtures studies analyzed
here (Table 2).
Beginning in the 1940s, DES was widely prescribed to some 5
million pregnant women under the mistaken assumption that it
prevented miscarriage. The discovery that gestational exposure
to DES induced a low incidence of clear cell vaginal adenocarinoma
in daughters and a low incidence of male reproductive abnormal-
ities in sons led to its removal from the market in 1972. Its
effects on sons exposed in utero, including epididymal cysts,
Fig. 4. DES potency comparison for male reproductive tract parameters. Human clinical data (ovals) Rat experimental data (triangles). Asterisks () denote no-effect doses.
Plus (+) denotes in utero administration. Pregnant women were assumed to weigh 70 kg. Where doses to rats were not reported per body weight, body weight data from
Klinger et al. (1996) or Pullen (1976) were used to calculate approximate administered doses. (a) Adamsson et al. (2008). In utero exposure to Sprague–Dawley dams. +⁄No
effect on fetal testicular T, Prog, StAR protein (steroidogenic acute regulatory protein), AR protein expression. (b) Filipiak et al. (2009). Administration on postnatal days 5–15
to Wistar pups. Reduced testes relative weight, seminiferous tubule diameter and length at puberty. (c) Goyal et al. (2001). Administration to 70–80 day old adult Sprague–
Dawely males for 12 days. (1) Markedly reduced plasma testosterone levels; (2) reduced size and number of Leydig cells and plasma testosterone barely detectable. (d) Goyal
et al. (2004). Administration every other day from postnatal days 2–12 to Sprague–Dawley pups: reduced penis weight, size and altered morphology; plasma testosterone
levels undetectable. (e) Goyal et al. (2005). Administration every other day from pnd 2–12 to Sprague–Dawley pups; dose calculated based on 10 g rat pup average, and not
averaged over days, i.e., plotted doses are overestimates. (1) Reduced weight of caudal epididymal fat pad (2) Reduced weights of caudal epididymal fat pad and seminal
vesicles. (3) Reduced weights of caudal epididymal fat pad, seminal vesicles, testis, and reduced penis diameter. (4) Reduced weights of caudal epididymal fat pad, seminal
vesicles, testis, and reduced penis diameter, weight and length. (f) Haavisto et al. (2001). In utero administration on embryonic days 13.5, 15.5 and 17.5 to Sprague–Dawley
dams. +(1) 50% reduction in fetal plasma and testicular testosterone levels. +(2) Reduced hCG-stimulated testosterone surge. (g) Haavisto et al. (2003). In utero administration
on embryonic days 13.5, 15.5 and 17.5 to Sprague–Dawley dams. +⁄(1) No-effects on fetal testicular and plasma testosterone. +(2) Reduced fetal testicular and plasma
testosterone. (h) Mathews et al. (2009). Administration on postnatal days 1–6 to male Sprague–Dawley pups. Reduced testes weight and altered epididymal morphology,
reduced androgen receptor expression and Leydig cell volume. (i) McKinnell et al., 2001. Administration to male Wistar rat pups every other day on postnatal days 2–12. (1)
38% reduction testes weight. (2) Reduced testes weight and altered epididymal morphology, reduced androgen receptor expression and 91% reduction in Leydig cell volume.
(k) Mikkilä et al. (2006). Subcutaneous doses administered on postnatal days 0–4 to male Sprague–Dawley pups. Reduced plasma testosterone, testis weight, seminiferous
cord diameter and steroidogenic acute regulatory protein expression. (A) Golden et al. (1998) and Dietrich (2010). Administration to pregnant women during weeks 7–35 of
pregnancy. +⁄(1) No adverse effects observed +(2) cryptorchidism, decreased penis size and sperm counts.
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sperm counts, and increased incidence of abnormal sperm
(Dietrich, 2010; Golden et al., 1998) have made DES the prototype
for chemical-induced TDS in humans, showing nearly identical ef-
fects in rats and humans (Toppari et al., 2010). Because no clinical
trial had been conducted with DES to verify efﬁcacy and optimize
dosage, the total DES dose administered varied among clinics by
more than an order of magnitude. Male reproductive tract abnor-
malities were signiﬁcantly increased only among offspring of
mothers enrolled in clinics that employed the higher dose
regimens, i.e., administration of 12–18 g DES during pregnancy
(Dietrich, 2010; Golden et al., 1998), or approximately 844–
1266 lg/kg/day, assuming a body weight of 70 kg per pregnant
woman. In contrast, no clear increase in incidence of male repro-
ductive tract effects has been observed in offspring of mothers gi-
ven lower dose regimens of DES, i.e., administration of 1.4 g DES
during pregnancy (Dietrich, 2010; Golden et al., 1998; Leary
et al., 1984), equivalent to 71 lg/kg/day for the ﬁrst two weeks
and 99 lg/kg/day during the entire pregnancy. Plotting these doses
against data from studies conducted in rats (Fig. 4) demonstrates
that effects on the developing male reproductive tract are observa-
ble in rats at DES doses approximately 1–2 orders of magnitude
lower than those required to produce similar effects in humans.
The data also indicate that the male rat reproductive tract is simi-
larly sensitive across fetal, neonatal and adult life stages.
In a detailed analysis of species differences with respect to in
utero DES-induced male reproductive tract anomalies, Hogan
et al. (1987) compared the relative potency ratios for these effects
in the mouse (the prototypical animal model for DES-induced
reproductive tract effects) and humans. Depending on various
assumptions, effects in humans occurred at doses from 1–2 orders
of magnitude greater, to approximately equal those at which
effects occurred in mice. Thus, both rat and mouse data challenge
the seemingly arbitrary assumption that male reproductive tract
malformations occur in humans at DES doses 200–500-fold less
than required to produce effects in rodents (Kortenkamp and Faust,
2010). Although there could be speculation on mechanisticgrounds as to why humans might be less sensitive than rodents
to effects of DES but not to effects of other chemicals with potential
anti-androgenic properties, such speculation would presumably be
irrelevant within the context of the DA–CAOS concept wherein
mechanistic similarity is not a criterion for predicting combination
effects. Consequently, the comparison of human versus rat sensi-
tivity to the effects of DES on the developing male reproductive
tract appears to be relevant for the risk assessment of anti-andro-
gens within the DA–CAOS concept, especially for phthalate esters.
This comparison would seem to be an obligate exercise for using
rat data to conduct a human health risk assessment, especially
when the data are publicly available.
2.5.2. Human versus rat – ﬁnasteride
To further test the assumption that anti-androgenic chemicals
affect the human male reproductive tract at doses lower than in
the rat, data were compared for effects of ﬁnasteride, a human
pharmaceutical prescribed for its anti-androgenic effects in the
treatment of benign prostatic hypertrophy (Gormley et al., 1990).
Finasteride was among the mixture of anti-androgens reported to
synergistically induce reproductive tract abnormalities in male rats
following in utero administration (Christiansen et al., 2009). Finas-
teride is a speciﬁc inhibitor of 5a reductase, the enzyme responsi-
ble for conversion of testosterone to dihydrotestosterone, the
active androgen receptor ligand and agonist in humans and ro-
dents. The inhibition of 5a reductase by ﬁnasteride is not mediated
through DHT binding to the androgen receptor, thus mimicking
hereditary 5a reductase deﬁciency where individuals with this
deﬁciency present with poor prostatic growth (Gormley, 1992;
Gormley et al., 1990). Finasteride has been shown to signiﬁcantly
reduce prostate size in humans and in several animal models. Both
testosterone and dihydrotestosterone (DHT) are critical for normal
male reproductive development. DHT is required for normal devel-
opment of the external genitalia and prostate (Bowman et al.,
2003).
Signiﬁcant variability attends establishing a threshold for per-
cent reduction in DHT in humans, as seen in Fig. 5. The lowest dose
Fig. 5. Finasteride potency comparison for human clinical suppression of DHT versus rat endpoints (see Table 3).
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and ranged from 10% after one-day exposure to 50–60% after 14-
day exposure (Gormley et al., 1990). In this study, a statistically
signiﬁcant percent reduction (approximately 40%) in DHT occurred
in the baseline values for two treatment groups, further indicating
the signiﬁcant variability if this effect. The maximum suppression
of DHT in serum is approximately 70% and occurs at doses >
0.007 mg/kg (Steiner, 1996). The plateau in suppression of serum
DHT is shown out to 1 mg/kg in Fig. 5. Maximum suppression of
DHT in the prostate is 85–90%. Finasteride has much greater afﬁn-
ity for the type 2 5a reductase isozyme than for the type 1, hence,
the remaining DHT in the serum and prostate gland is likely to be
the result of type 1 5a reductase (Bartsch et al., 2002).
Very little data were found to establish a threshold for the
reduction of serum DHT in the rat. A threshold for the effect of
DHT on the prostate has been demonstrated in rats, however the
threshold is only apparent when the animals have been castrated,
resulting in very low intra-prostatic testosterone and DHT levels
(Bartsch et al., 2002). Thresholds for effects on male reproductive
development in the rat using both standard developmental toxicity
studies and the Hershberger assay are also shown in Fig. 5. Finas-
teride causes a decrease in anogenital distance in male offspring.
The threshold for reversible decreased anogenital distance is
0.003 mg/kg (Clark et al., 1990) but is somewhat higher for irre-
versible decreased anogenital distance as determined by its pres-
ence at post-natal day 90 (Bowman et al., 2003).
Fig. 5 shows that the threshold for a clinically effective decrease
(Fig. 5J) in circulating dihydrotestosterone in men occurs at
approximately the same ﬁnasteride dose as produces a reduction
in rat anogenital distance in the Hershberger assay (Fig. 5I).
Thresholds for other effects in rats are observed at signiﬁcantly
higher doses, but still lower than the recommended clinical dose
for treatment of benign prostatic hypertrophy in men (Fig. 5S).
Taken together, the above data strongly suggest that irrespective
of the high variability in both human and rat data, effects of a
potent anti-androgen, ﬁnasteride, occur in human males at doses
no lower than, and most likely considerably higher than are re-
quired to produce effects in the rat.3. The Human-Relevant Potency-Threshold (HRPT)
As a conservative screening level assessment, the DA–CAOS
concept may have some utility since it is reasonably simple to per-
form, requires only rudimentary dose–response information and
demands virtually no understanding of mode of action, pharmaco-
kinetics, or structure activity relationships. However, as demon-
strated above, the DA–CAOS theory suffers an inordinate degree
of uncertainty as evidenced by limitations in the studies on which
it is based, contradicts fundamental tenets of pharmacology, and
would predict outcomes incongruous with human clinical and epi-
demiological observations. The published risk assessment based on
DA–CAOS magniﬁes those uncertainties with unnecessary conser-
vatism regarding doses at which effects occur in humans versus
rats. Thus, for any group of chemicals that warrant further analysis
– for which concern might remain after conducting a DA–CAOS
screening assessment – a better approach is needed that is well
grounded in fundamental pharmacological principles, can be rec-
onciled with human clinical data, and is consistent with clinical
epidemiological experience.
Consequently, an improved risk assessment and prediction
strategy is proposed that melds those features of the DA–CAOS
concept that are tenable with requirements of the TEQ concept that
are necessary to conform with fundamental pharmacological prin-
ciples and to be compatible with the observed clinical and epide-
miological data. The proposed approach, referred to as the
Human Relevant Potency Threshold (HRPT) approach, proposes
that DA be assumed for chemicals that can affect a common ad-
verse outcome, but only at doses close to the lower limit of the ob-
servable effect range. It also proposes that DA be applied to
chemicals that meet the TEQ requirements for receptor- or en-
zyme-mediated adverse effects and whose potency approaches
that of an endogenous ligand or human pharmaceutical. In both
cases, the observable effect dose or the potency of a natural ligand
or human pharmaceutical should be based on human data when-
ever available. Below these ‘thresholds’ in either dose or potency
(afﬁnity/intrinsic activity), IA would be used for cumulative risk
assessment of chemicals to which humans are exposed; i.e.,
Table 3
Human clinical data (ovals) rat experimental data (triangles). Blue points indicate % reduction in DHT.
Dose (mg/kg) Human endpoint Rat endpoint Reference
0.0001 Neg Hershberger assay Ashby et al. (2004) A
0.0005 Neg Hershberger assay Ashby et al. (2004) B
0.0006 (1 day) 10% ; serum DHT Gormley et al. (1990) C
0.0006 (14 days) 50–60% ; serum DHT Gormley et al. (1990) D
0.001 Neg Hershberger assay Ashby et al. (2004) E
0.0018 (1 day) 50–60% ; serum DHT Gormley et al. (1990) F
0.0018 (14 days) 50–60% ; serum DHT Gormley et al. (1990) G
0.002 Neg Hershberger assay Ashby et al. (2004) H
0.003 Threshold for ; AGD at PND 1 Clark et al. (1990) I
0.0031 (1 day) 35% ; serum DHT Gormley et al. (1990) J
0.0031 (14 days) 65% ; serum DHT Gormley et al. (1990) K
0.005 Neg Hershberger assay Ashby et al. (2004) L
0.007 Reported threshold for maximal
clinical suppression of DHT
Steiner (1996) M
0.008 Threshold in Hershberger assay based on ; prostate and glans
penis weight
Ashby et al. (2004) N
0.01 Threshold for ; AGD at PND 90 Bowman et al. (2003) O
0.01 Threshold for reversible male nipple retention Bowman et al. (2003) P
0.015 64% ; serum DHT, Suboptimal ;
prostate volume in 6–12 mos,
Suboptimal " urinary ﬂow in 6–12
mos
McConnell (1992) Q
Gormley (1992)
Gormley (1992)
0.03 Threshold for permanent male nipple retention Bowman et al. (2003) R
0.077 Recommended clinical dose (5 mg),
59–71% ; serum DHT, Max ; prostate
volume in 6–12 mos (19–26% ;),
Optimal " urinary ﬂow in 6–12 mos
Bartsch et al., 2002 S
Gormley (1992)
0.1 Threshold for hypospadias Clark et al. (1990) T
0.15 71% ; serum DHT McConnell (1992) U
0.2 +Hershberger assay (seminal vesicle wgt only) Kennel et al. (2004) V
0.2 Reported Hershberger LOELs (multiple tissues) Owens et al. (2007) W
0.77 85% ; serum DHT McConnell (1992) X
0.77 Lowest BMD for Hershberger assays Owens et al. (2007) Y
1.54 78% ; serum DHT, Maximum clinical
dose
McConnell (1992) Z
20 <45% ; serum DHTa, 30% " serum T, ; epididymal, prostate, SV wgt,
No effect on testis wgt
Marty et al. (2001) AA
80 45% ; serum DHTa, 30% " serum T, ; epididymal, prostate, SV wgt Marty et al. (2001) BB
a Not statistically signiﬁcant.
Fig. 6. HRPT conceptual model. Different line patterns a–e represent chemicals
with anti-androgenic potential that produce CAOS via different modes of action. (S)
indicates the dose range where mixture experiments (Table 2) have been performed
relative to the dose–response curves for observable effects (Q). The HRPT approach
proposes that DA be assumed for chemicals that can affect a common adverse
outcome, but only at doses (S1) that approach the lower limit of the observable
effect range (Q), as depicted in the top panel. For cumulative risk assessments, IA
would be used to combine chemicals to which humans are exposed that fall below
these ‘thresholds’ (S2, bottom panel) in either dose or potency.
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tion rather than hazard indices.
The HRPT approach accommodates both the DA–CAOS concept,
where tenable, and the well-established TEQ concept, but im-
proves upon each by providing a means for calibrating the assump-
tion of DA with human data. The approach is broadly applicable
whenever human data are available to support estimation of hu-
man-relevant thresholds. A conceptual diagram of the HRPT ap-
proach is presented in Fig. 6, which can be clearly contrasted
with the DA–CAOS concept as depicted in Fig. 2b. Although the
HRPT approach will not be possible for all chemicals due to lack
of human data, the HRPT approach will be feasible in many cases,
including any adverse outcome or intermediate step in the produc-
tion of an adverse outcome that can be produced by a human phar-
maceutical agent. For the pharmaceutical agents considered in this
manuscript, DES and ﬁnasteride, clinical and rodent data were
readily available in the published literature.
The steps necessary for applying the HRPT approach in cumula-
tive (combined exposures) risk assessment include:
1. Deﬁning the common adverse outcome or target organ effect
upon which the cumulative effect from a group of chemicals
is to be based. In most instances, this will be deﬁned based on
animal toxicology studies, but care should be taken to avoid
effects that are arguably species speciﬁc and of questionable
relevance to humans. It is important that the effect is deﬁnedspeciﬁcally and that constellations of effects be avoided unless
clearly and deﬁnitively related by physiological and mechanis-
tic understanding.
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adverse outcome in the test species and determining whether
data indicate DA combined effects of those chemicals. If demon-
strable, identify the lowest concentrations in mixtures at which
DA occurs.
3. Deﬁning, if possible, the modes of action that can lead to the
adverse outcome in the test species.
4. Identifying chemicals, including drugs, known to produce the
adverse outcome in humans, including among these, chemicals
or drugs known to operate by relevant modes of action that can
produce the adverse outcome.
5. Identifying chemicals for which the TEQ concept is justiﬁed
based on satisfying TEQ requirements (see Table 1).
6. Gathering and comparing dose–response data for the chemicals
and drugs of interest in humans and the test species, whether
based on end-organ toxic effects or intermediate, obligate steps
in the production of toxicity. An example of the former is the
comparison of the DES doses at which male reproductive tract
malformations occur in humans versus rats; the latter, the com-
parisons based on doses of ﬁnasteride. Fortunately, because
data providing direct dose sensitivity comparisons for frank
adverse effects are rare, such as those for DES, comparisons
based on measures of pharmacological effects will often be
required.
7. Based on the comparisons of human versus test species sensi-
tivity, potency differences between chemicals, and concentra-
tions at which DA adverse effects are demonstrable in test
species, estimating the potency differential between species,
and thus the potency threshold at which DA would be a conser-
vative but tenable assumption for humans. Deﬁning these
potency thresholds is required for TEQ-compliant chemicals
as well as for broader groups based only on common adverse
outcome or intermediate steps in toxicity.
4. Application of the HRPT approach to potential anti-
androgens
The ﬁrst three steps for applying the HRPT approach as outlined
above were assumed from the NRC report (NRC, 2008) and the
mixtures studies conducted on chemicals with potential anti-
androgenic properties (see Table 2). Step 4 involved identiﬁcation
of DES as a chemical known to produce the common adverse out-
come in humans, and identiﬁcation of ﬁnasteride, a chemical in-
cluded in the one of the subject mixtures studies (Christiansen
et al., 2009) which has a deﬁned mode of action and clearly mea-
surable clinical endpoint in humans. Chemicals that are potent
inhibitors of 5-alpha reductase, androgen receptor antagonists,
and phthalate esters that interrupt Leydig and Sertoli cell develop-
ment may be candidates for three separate TEQ groupings (Step 5).
Step 6 has been outlined previously in this paper and is summa-
rized in Figs. 4 and 5. Step 7 is described below using phthalate es-
ters and ﬁnasteride as examples to illustrate how the HRPT
approach is applied based on dose level and potency respectively.
For the broad grouping of chemicals with potential anti-andro-
genic properties, an HRPT should be set on dose level rather than
potency because these chemicals do not satisfy TEQ criteria for
application of DA across untested dose ranges. Based on the anal-
ysis outlined in steps 1 through 6 and the analysis presented in
Section 2.4.1 and Fig. 4, a proposed dose-based HRPT for the broad
grouping of phthalate esters and other chemicals with potential
anti-androgenic properties can be conservatively set at doses 5-
fold below rat LOAELs/NOAELs for CAOS on the developing male
reproductive tract. Thus, for example, the HRPT approach would
apply DA to combined human phthalate exposures that are within
a factor of 5-fold lower (i.e., 20%) than rat LOAELs/NOAELs for ef-
fects on the male reproductive tract, but would apply IA to lowerexposure levels, i.e., for cumulative risk assessment at current lev-
els of human exposure to phthalates. Since the DES dose required
for human in utero effects is approximately 1–2 orders of magni-
tude greater than required for rats (Fig. 4), an HRTP above the rat
LOAELs/NOAELs may be justiﬁable. Thus, the proposed dose-based
HRPT of 5-fold below the rat LOAELs/NOAELs for assuming DA in a
cumulative risk assessment is a conservative estimate for TDS-like
effects on the developing male reproductive tract of humans, and
likely provides at least an additional order of magnitude conserva-
tism. Although the DA–CAOS concept does not require a mechanis-
tic rationale for estimating combined effects, the fact that both
phthalates and DES produce effects on the developing male repro-
ductive tract secondary to inhibition of Leydig and Sertoli cell func-
tion provides relatively high conﬁdence that a dose-based HRPT of
5-fold below the rat NOAEL is adequately protective of human
health.
Over the past decade, a number of epidemiology studies have
appeared in the scientiﬁc literature that compared urinary concen-
trations of phthalate metabolites and developmental effects in in-
fants, including anti-androgenic effects (e.g., cryptorchidism,
anogenital distance). Those studies have a number of features in
common: a proposed hypothesis based on the results of animal
studies, limited populations, limited number of biomarker samples
during pregnancy, and limited concurrence with animal data.
Although virtually all of the studies report one or more statistically
signiﬁcant associations, none offer a basis for testing the HRPT ap-
proach on the potential for anti-androgenic effects in infants ex-
posed to individual or multiple phthalates. Causal interpretation
of the epidemiological ﬁndings is problematic due to several limit-
ing factors, which are often well described by the investigators. In
addition, there is a considerable amount of inconsistency among
the human studies and between the animal and human studies.
Human versus rat comparisons for the potency of ﬁnasteride
suggest a conservative potency-based HRPT of 1 order of magni-
tude below the potency of ﬁnasteride for effects on the rat male
reproductive tract from androgen deﬁciency via inhibition of 5-al-
pha-reductase. This potency-based HRPT would be applied to
chemicals meeting TEQ criteria for similarity of mode of action
and structure–activity parameters with ﬁnasteride, and provides
approximately an order of magnitude conservatism based on data
indicating that humans have similar sensitivity as rats to effects of
ﬁnasteride, as explained above in Section 2.4.2 and illustrated in
Fig. 5. This potency-based HRPT would trigger the assumption of
DA for all chemicals meeting TEQ criteria whose potency for inhi-
bition of 5-alpha reductase is within one order of magnitude that
of ﬁnasteride. Chemicals with lower potency would be assessed
by IA, or by DA using an HRPT set on dose, in this instance, at doses
within 5-fold below their individual NOAELs/LOAELs for CAOS on
the developing male reproductive tract. Although we have not de-
rived potency-based HRPTs speciﬁcally for androgen receptor
antagonists or for inhibitors of particular enzymes in the steroido-
genic pathway, these would be derived as was done for ﬁnasteride
if cumulative assessments are desired for exposure to groups of
chemicals that act speciﬁcally by these modes of action.
Applying the HRPT approach to the risk assessment for 15 anti-
androgens results in an estimate of risk for phthalates 2 or more
orders of magnitude lower than concluded in the published assess-
ment (Kortenkamp and Faust, 2010). This is due to the fact that a
conservative HRPT of 5-fold below the rat NOAEL precludes appli-
cation of DA to lower human exposures, whereas Kortenkamp and
Faust (2010) assumed DA for all doses and ratios based on human
RfDs 200–500-fold lower than rat NOAELs. In contrast, use of the
more biologically plausible HRPT approach leads to a conclusion
that under current exposure conditions, phthalates should not be
assessed by DA, and that few, if any of the other chemicals included
in the published risk assessment (Kortenkamp and Faust, 2010)
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should be applied to those chemicals.5. Conclusions
Limitations in the study designs for mixtures of rodent anti-
androgens (Table2), albeit imposed by practical necessity for stud-
ies in live animals, impart an undeﬁned level of uncertainty to the
extrapolation of experimental results beyond the doses and ratios
tested. Additional uncertainty is introduced by the use of scored
endpoints and the way these scores were combined for some anal-
yses. A statistical analysis of precision using published data from the
mixtures studies in question indicates that the model predictions
may vary as much as 2-fold for the dose ratio and concentrations
of chemicals tested. This variance would expandwith extrapolation
to untested ratios and doses. Extrapolation to lower doses is totally
dependent on the model employed and because no data exist to
support the extrapolation, this could dramatically increase variabil-
ity and lead to erroneous conclusions. These factors reduce the con-
ﬁdence that can be placed in the conclusion that mixtures of anti-
androgens are DA, even within the dose ranges evaluated, but even
moreso at untested concentrations and ratios. Noobjective informa-
tion allows one to conclude that DA is more accurate than IA at rel-
evant human exposure levels. Given the questions raised here
(Section 2.2) and the fact that the Rider et al. (2008) and Metzdorff
et al. (2007) data, taken together, indicate that DA as well as IA pre-
dict a variety of relevant responses in the developing male repro-
ductive tract of rats, it is unclear if not unscientiﬁc to assume DA
by default based on a preference for conservatism, as claimed (Kor-
tenkamp and Faust, 2010). Since risk management decisions often
involve choosing between various options, it is impossible to make
those decisions in a precautionarymodewithout understanding the
underlying accuracy of scientiﬁc assessments. Therefore, the prefer-
ence of models used to scientiﬁcally assess human health risks
would be best based on data rather than on presumptions about
what constitutes a precautionary decision.
The DA–CAOS theory is inconsistent with established pharma-
cological principles that relate afﬁnity, intrinsic activity, and efﬁ-
cacy to relative potency estimation, and overlooks potential
dose-dependent changes in pharmacokinetic interactions. Logical
predictions of the DA–CAOS concept are also inconsistent with
available clinical and epidemiological information. The incidence
of TDS in humans, considered by some to be consistent with
phthalate syndrome in rats, is quite low, whereas applying the
DA–CAOS theory to all potential anti-androgenic drugs and chem-
icals would predict an epidemic of the syndrome affecting nearly
the entire human population. The strong suggestion of a clinical
threshold for DES-induced male reproductive tract malformations
is inconsistent with the assumption of DA–CAOS, given the fact
that human exposure to many anti-androgenic drugs and chemi-
cals was signiﬁcant during the DES episode. If combined exposures
to chemicals that can affect a CAOS truly operate by DA irrespec-
tive of their potencies and concentrations, it is difﬁcult to imagine
how living organisms could survive in a world composed of hun-
dreds of thousands of chemicals, all of which produce overt toxicity
at some level of exposure. Indeed, the DA–CAOS theory contra-
venes well-established principles of pharmacological and toxico-
logical action evidenced by mechanistic and clinical data derived
from human pharmaceutical experience.
Comparison of published data for human and rat male repro-
ductive tract sensitivities to DES and ﬁnasteride reveals that rely-
ing on rat data while ignoring the relative sensitivity of the
human fetus has introduced considerable but unnecessary uncer-
tainty and conservatism to the published human health risk
assessments for anti-androgens (Kortenkamp and Faust, 2010;Benson, 2009). The magnitude of this unnecessary conservatism
is at least 2 orders of magnitude, and perhaps as much as 4 orders
of magnitude. Taken together, the uncertainties and conservatism
introduced by applying DA to all anti-androgens at all doses, irre-
spective of mechanism, and ignoring human versus rat sensitivity
render scientiﬁc conclusions based on the mixture studies at issue
tenuous and regulatory decisions based on the risk assessment uti-
lizing such studies arbitrary.
The DA–CAOS recommendation and the risk assessment based
upon it are radical departures from past EPA practice regarding
similarity criteria for applying dose addition (Table 1)(Borgert
et al., 2004). Furthermore, this approach appears to ignore the en-
tire logic of the TEQ requirements, which were developed as inclu-
sion criteria for applying DA in cumulative risk assessments, i.e., to
increase the reliability of extrapolating the DA assumption beyond
empirical data. Nonetheless, because sophisticated pharmacologi-
cal and toxicological knowledge is not required for its application,
the DA–CAOS concept could be rationally applied, but only as a
coarse screening level assessment. This is consistent with the his-
torical use of hazard-index based approaches, which are used in
screening-level baseline risk assessments to project acceptable
cleanup criteria for hazardous waste sites.
If a DA–CAOS-type assessment suggests that human exposure
to some groups of chemicals may exceed its conservative parame-
ters, a more biologically based method of assessing actual risk is
warranted. We have proposed such a method – the HRPT approach
– to fulﬁll this need. The HRPT approach builds upon tenable
assumptions of the DA–CAOS approach and the more biologically
based TEQ approach used for decades by EPA and other regulatory
bodies, but offers a means of improving the accuracy and reliability
of the risk assessment by incorporating human data into the po-
tency and combined-effect analysis. The HRPT approach is widely
applicable and is feasible for any type of effect that is produced
by groups of chemicals for which direct human data are available.
Given the wide array of pharmacological modalities by which hu-
man pharmaceuticals act, sufﬁcient data are available for applying
the HRPT approach broadly in toxicological risk assessment.6. Conﬂict of interest statement
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